Financials
Financial year 2025
ASTEL MEDICA from Neupré, company number BE0472890044, closed financial year 2025 with a result of € 470,529 after tax. For that financial year ASTEL MEDICA recorded a gross margin of € 2.1 million and equity of € 1.4 million. Compared with financial year 2024, the result moved from € 798,825 to € 470,529. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 1.4 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 470,529
▼ 41% vs 2024
Profit after tax over the fiscal year.
€ 228,157
▼ 70% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 470,000 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
14.6
▼ 7.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.2 million
▼ 31% vs 2024
€ 85,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 177,873
▼ 44% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 348,961
▼ 57% vs 2024
€ 117,801 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 228,998
▼ 28% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 151,153
▼ 47% vs 2024
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 2,546,069 | € 1,685,542 | € 3,197,679 | € 2,136,686 | ▼ 33% |
| Profit after taxes | € 548,032 | € 259,497 | € 798,825 | € 470,529 | ▼ 41% |
| Equity | € 1,295,618 | € 1,292,307 | € 1,407,298 | € 1,406,880 | |
| Total debts | € 2,375,723 | € 1,523,426 | € 2,211,005 | € 1,199,358 | ▼ 46% |
| Cash | € 391,316 | € 432,168 | € 759,208 | € 228,157 | ▼ 70% |
| Land & buildings | € 1,000,205 | € 998,469 | € 854,404 | € 798,544 | ▼ 7% |
| Retained profit | € 1,224,248 | € 1,223,745 | € 1,282,352 | € 1,282,880 | |
| Dividend | € 670,000 | € 260,000 | € 795,000 | € 470,000 | ▼ 41% |
| Bank debt | € 1,050,497 | € 833,923 | € 813,015 | € 348,961 | ▼ 57% |
| Balance sheet total | € 3,713,444 | € 2,856,901 | € 3,657,600 | € 2,645,219 | ▼ 28% |
| Employees (FTE) | 23.4 | 15.1 | 22.5 | 14.6 | ▼ 7.9 |
Key figures of ASTEL MEDICA, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ASTEL MEDICA?
What happened at ASTEL MEDICA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 470,529 (▼ 41% vs 2024). Source: NBB ↗
- New establishment in Neupré. KBO
- Start of the company according to the CBE. KBO
In short
From € 548,032 profit in 2021 to € 470,529 profit in 2025.
Paid € 783,287 in corporate taxes since 2021.
Best year ever: 2024, with € 798,825 profit.
On average € 146,300 of value added per employee in 2025.
Management
Behind ASTEL MEDICA is Thouria Louhmadi.
Directors
According to the 2025 annual accounts
Thouria Louhmadi
Director
Establishments
Establishment units
Physical locations of this company
Route du Condroz(RR) 109/4
4120 Neupré
Route du Condroz(RR) 109 box 4
4120 Neupré
Active since 24 October 2000
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0472.890.044
- VAT number
- BE 0472.890.044
- Registered office
- Route du Condroz(RR) 109/4, 4120 Neupré
- Names & denominations
- ASTEL MEDICA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 2 October 2000
- Peppol
- Active · Active since 11 Sept 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Vervaardiging van geneesmiddelen